InteRNA Technologies and Radboud University Nijmegen Medical Centre said this week that they have agreed to collaborate on the development of microRNA-based therapeutics for prostate cancer.
Under the research arrangement, InteRNA's lentiviral-based miRNA over-expression library "will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer," the partners said.
Additional terms were not disclosed.